Bristol-Myers Squibb Co. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| BMY | LLY | |
|---|---|---|
| Market Cap | $129.92 billion | $1.03 trillion |
| Revenue (TTM) | $49.19 billion | $79.67 billion |
| Net Income (TTM) | $9.27 billion | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| BMY | LLY | |
|---|---|---|
| P/E Ratio | 13.84 | 38.69 |
| Price / Book | 5.82 | 30.32 |
| Price / Sales | 2.64 | 12.89 |
BMY leads on 3 of 3 valuation factors.
Profitability
| BMY | LLY | |
|---|---|---|
| Net Margin | 18.85% | 33.53% |
| Return on Equity | 41.55% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| BMY | LLY | |
|---|---|---|
| Dividend Yield | 4.01% | 0.60% |
| Payout Ratio | 55.51 | 23.23 |
BMY and LLY split the dividend factors evenly.
Risk & Sentiment
| BMY | LLY | |
|---|---|---|
| Short Interest | 0.39% | 1.29% |
BMY leads on 1 of 1 risk & sentiment factors.
Dig deeper: BMY overview, BMY financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
